Compare BEKE & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEKE | ONC |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 34.8B |
| IPO Year | 2020 | N/A |
| Metric | BEKE | ONC |
|---|---|---|
| Price | $17.34 | $319.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $24.36 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 4.6M | 279.4K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.42 | ★ 0.58 |
| Revenue | ★ $14,540,474,652.00 | $4,972,687,000.00 |
| Revenue This Year | $7.14 | $895.40 |
| Revenue Next Year | $4.90 | $22.04 |
| P/E Ratio | ★ $41.98 | $514.97 |
| Revenue Growth | 25.42 | ★ 50.43 |
| 52 Week Low | $15.39 | $170.99 |
| 52 Week High | $25.17 | $385.22 |
| Indicator | BEKE | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 41.76 |
| Support Level | $16.14 | $315.50 |
| Resistance Level | $17.66 | $326.77 |
| Average True Range (ATR) | 0.31 | 11.23 |
| MACD | 0.09 | -3.05 |
| Stochastic Oscillator | 80.00 | 18.85 |
KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies, including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2024, Beike's co-founders collectively control the company, while Tencent and its affiliates share 8% of voting power.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.